Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 1

Status

Completed 4Recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 5Prostatic Neoplasms, Castration-Resistant 1Prostate Cancer Metastatic 1Neoplasms 1

Interventions

Docetaxel 292Prednisone 241enzalutamide 195Leuprolide 185Radiotherapy 179Abiraterone Acetate 170Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 93abiraterone 83gallium 68 PSMA-11 81Specimen Handling 73darolutamide 67Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 53Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Prostatic Neoplasms × fludrocortisone acetate × Clear all
NCT06136650 2026-06-03

MK-5684-004

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,314 enrolled
Genitourinary

Prostatic Neoplasms

NCT06104449 2026-04-27

MK-5684-005

Merck Sharp & Dohme LLC

Phase 1 Completed
7 enrolled
Genitourinary

Prostatic Neoplasms

NCT06136598 2026-03-19

MK-5684-001

Merck Sharp & Dohme LLC

Phase 1 Completed
14 enrolled
Genitourinary

Prostatic Neoplasms

NCT06566989 2024-10-23

MK-5684-008

Merck Sharp & Dohme LLC

Phase 1 Completed
8 enrolled
Genitourinary

Prostatic Neoplasms

NCT06554639 2024-10-15

MK-5684-011

Merck Sharp & Dohme LLC

Phase 1 Completed
12 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡